Paper Details

  1. Home
  2. Paper Details

Lomustine and Bevacizumab in Progressive Glioblastoma.

Author: BendszusMartin, BrandesAlba A, BrombergJacoline C, CamponeMario, ClementPaul M, DomontJulien, DuboisFrancois, FabbroMichel, GolfinopoulosVassilis, GorliaThierry, HartingInga, IdbaihAhmed, KleinMartin, Le RhunEmilie, PlattenMichael, SahmFelix, StuppRoger, TaalWalter, TaphoornMartin, WellerMichael, WickWolfgang, van den BentMartin J, von DeimlingAndreas

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study aimed to determine whether combining bevacizumab with lomustine would result in longer overall survival than lomustine alone in patients with glioblastoma at first progression.
Paper Details　
Original Abstract of the Article :
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1707358

データ提供：米国国立医学図書館（NLM）

Lomustine and Bevacizumab: A Powerful Combination for Glioblastoma Treatment?

This research dives into the complex world of glioblastoma, an aggressive type of brain cancer that presents significant challenges for treatment. The study investigates the potential benefits of combining two drugs, lomustine and bevacizumab, to improve patient outcomes. The researchers sought to determine if this combination would result in longer overall survival compared to lomustine alone, especially for patients who have experienced disease progression. The study was based on previous research suggesting that the combination might be more effective than monotherapies. The findings of this study are crucial for informing treatment decisions and potentially improving the lives of patients with glioblastoma.

Combating Glioblastoma: Seeking New Avenues for Treatment

This research underscores the ongoing quest for more effective treatments for glioblastoma. It's like a group of explorers venturing into uncharted territory, seeking new routes and strategies to overcome this formidable foe. The study’s findings provide valuable insights into the potential of combining lomustine and bevacizumab, offering hope for improving patient outcomes in the future. The results of this study are particularly important for patients experiencing disease progression, as they may benefit from the combination therapy.

Glioblastoma: A Complex Challenge and a Continuing Quest for Solutions

Glioblastoma is a complex and challenging disease, much like the shifting sands of a desert. The search for effective treatments is a continuous journey, and this study provides valuable insights into the potential of combining lomustine and bevacizumab. Understanding the effectiveness of different treatment approaches is crucial for providing optimal care to patients and offering hope for the future.

Dr. Camel's Conclusion

This research represents a significant step forward in the battle against glioblastoma. It highlights the importance of exploring new treatment strategies and evaluating their effectiveness in clinical trials. It's like a camel caravan seeking a better route across the desert, pushing the boundaries of what's possible and paving the way for improved patient care.
Date :
  1. Date Completed 2017-12-01
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29141164

DOI: Digital Object Identifier

10.1056/NEJMoa1707358

Related Literature

Article Analysis
・Effects of lomustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.